0

Close
 
Upcoming Allied Market Research
2023
Companion Animal Pharmaceuticals Market

Companion Animal Pharmaceuticals Market: Global Opportunity Analysis and Industry Forecast, 2021-2030 Market

LS : Pharmaceuticals
Report Code: A12309
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Companion Animal Pharmaceuticals Market

Request Now !

A companion animal is a non-assistive animal used for psychological support, amusement, company, extrovert display, and several other functions that a human needs to share with animals. Dogs, cats, horses, birds, mice, and guinea pigs are some of the animals that can be considered as companion animals. Numerous studies have shown that positive health benefits, such as lowered blood pressure, decreased anxiety, decreased cardiac arrhythmias, greater psychological stability, and improved well-being are associated with owning a companion animal. Furthermore, companion animal pharmaceuticals are used to sedate, treat, and improve their health and performance. It is essential to take care of these animals and provide essential health services to them.

COVID-19 scenario analysis

The coronavirus pandemic is having a huge impact on businesses and has already caused an unprecedented collapse of economic activities. The COVID-19 impact is straining the healthcare systems globally and has disrupted the supply chain for the companion animal pharmaceuticals market, temporarily leading to a decline in the demand for these products. The rapidly increasing demand for healthcare facilities and healthcare workers may leave only a few healthcare systems to meet the increasing demand during the pandemic situation.

Although there has been no evidence or confirmation that animals can spread COVID-19 to humans, the myth that animals can spread the virus to humans has increased the number of abandoned pets. Furthermore, COVID-19 has weakened the supply chain and has created shortage of animal health products such as nutritional feed as well as vaccines globally. The animal health industry has been largely impacted, as many manufacturers in animal health industry are left with a significantly reduced workforce. Moreover, implementation of stringent government policies such as restrictions of import of raw materials from China is expected to hamper the animal health market.

Healthcare facilities are stocking up animal-related health products, considering the high demand. This is expected to further create financial strain on the market due to procurement inefficiencies and wasted speeding. Due to the pandemic situation, many hospitals and veterinary clinics are overstocking the products.

Top impacting factors: market scenario analysis, trends, drivers, and impact analysis

With surge in companion animal population and increase in animal health expenditure, many players from international markets are focusing on investing in this particular market. Moreover rise in prevalence of zoonotic diseases such as rabies, salmonellosis, plague, brucellosis, and Lyme are major concern among animal keepers, which is driving the growth of the companion animal pharmaceuticals market. The market is being restrained by lack of awareness about animal healthcare and rise in pet care cost.

Key benefits of the report

  • This study presents the analytical depiction of the global companion animal pharmaceuticals market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions answered in the companion animal pharmaceuticals market report

  • Which are the leading players active in the companion animal pharmaceuticals market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in taking further strategic steps?

 Companion Animal Pharmaceuticals Market: Global Opportunity Analysis and Industry Forecast, 2021–2030 Report Highlights

Aspects Details
By Companion Animals
  • Dogs
  • Cats
  • Horses
  • Others
By Drug Class
  • Antibiotics
  • Anti-inflammatory
  • Heart Worm Drugs
  • Parasiticides
  • Nutritional Drugs
  • Behavioral Drugs
  • Vaccines
  • Others
By Distribution Channel
  • Veterinary Pharmacies
  • E-commerce
  • Retail Pharmacies
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Ceva Santé Animale, Zoetis, Eli Lily, Merck & Co., Inc., Virbac, Agrolabo S.p.A., IDEXX Laboratories, Inc., Elanco Animal Health Incorporated, Indian Immunologicals Ltd., Boehringer Ingelheim International GmbH, Vetoquinol S.A.
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COMPANION ANIMALS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Companion Animals

    • 4.2. Dogs

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Cats

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Horses

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Others

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DRUG CLASS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Drug Class

    • 5.2. Antibiotics

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Anti-inflammatory

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Heart Worm Drugs

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Parasiticides

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Nutritional Drugs

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Behavioral Drugs

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

    • 5.8. Vaccines

      • 5.8.1. Key Market Trends, Growth Factors and Opportunities

      • 5.8.2. Market Size and Forecast, By Region

      • 5.8.3. Market Share Analysis, By Country

    • 5.9. Others

      • 5.9.1. Key Market Trends, Growth Factors and Opportunities

      • 5.9.2. Market Size and Forecast, By Region

      • 5.9.3. Market Share Analysis, By Country

  • CHAPTER 6: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Veterinary Pharmacies

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. E-commerce

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Retail Pharmacies

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Companion Animals

      • 7.2.3. Market Size and Forecast, By Drug Class

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Companion Animal Pharmaceuticals Market

        • 7.2.6.1. Market Size and Forecast, By Companion Animals
        • 7.2.6.2. Market Size and Forecast, By Drug Class
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Companion Animal Pharmaceuticals Market

        • 7.2.7.1. Market Size and Forecast, By Companion Animals
        • 7.2.7.2. Market Size and Forecast, By Drug Class
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Companion Animal Pharmaceuticals Market

        • 7.2.8.1. Market Size and Forecast, By Companion Animals
        • 7.2.8.2. Market Size and Forecast, By Drug Class
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Companion Animals

      • 7.3.3. Market Size and Forecast, By Drug Class

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Companion Animal Pharmaceuticals Market

        • 7.3.6.1. Market Size and Forecast, By Companion Animals
        • 7.3.6.2. Market Size and Forecast, By Drug Class
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Companion Animal Pharmaceuticals Market

        • 7.3.7.1. Market Size and Forecast, By Companion Animals
        • 7.3.7.2. Market Size and Forecast, By Drug Class
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Companion Animal Pharmaceuticals Market

        • 7.3.8.1. Market Size and Forecast, By Companion Animals
        • 7.3.8.2. Market Size and Forecast, By Drug Class
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Companion Animal Pharmaceuticals Market

        • 7.3.9.1. Market Size and Forecast, By Companion Animals
        • 7.3.9.2. Market Size and Forecast, By Drug Class
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Companion Animal Pharmaceuticals Market

        • 7.3.10.1. Market Size and Forecast, By Companion Animals
        • 7.3.10.2. Market Size and Forecast, By Drug Class
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Companion Animal Pharmaceuticals Market

        • 7.3.11.1. Market Size and Forecast, By Companion Animals
        • 7.3.11.2. Market Size and Forecast, By Drug Class
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Companion Animal Pharmaceuticals Market

        • 7.3.12.1. Market Size and Forecast, By Companion Animals
        • 7.3.12.2. Market Size and Forecast, By Drug Class
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Companion Animals

      • 7.4.3. Market Size and Forecast, By Drug Class

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Companion Animal Pharmaceuticals Market

        • 7.4.6.1. Market Size and Forecast, By Companion Animals
        • 7.4.6.2. Market Size and Forecast, By Drug Class
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Companion Animal Pharmaceuticals Market

        • 7.4.7.1. Market Size and Forecast, By Companion Animals
        • 7.4.7.2. Market Size and Forecast, By Drug Class
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Companion Animal Pharmaceuticals Market

        • 7.4.8.1. Market Size and Forecast, By Companion Animals
        • 7.4.8.2. Market Size and Forecast, By Drug Class
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Companion Animal Pharmaceuticals Market

        • 7.4.9.1. Market Size and Forecast, By Companion Animals
        • 7.4.9.2. Market Size and Forecast, By Drug Class
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Companion Animal Pharmaceuticals Market

        • 7.4.10.1. Market Size and Forecast, By Companion Animals
        • 7.4.10.2. Market Size and Forecast, By Drug Class
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Companion Animal Pharmaceuticals Market

        • 7.4.11.1. Market Size and Forecast, By Companion Animals
        • 7.4.11.2. Market Size and Forecast, By Drug Class
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Companion Animal Pharmaceuticals Market

        • 7.4.12.1. Market Size and Forecast, By Companion Animals
        • 7.4.12.2. Market Size and Forecast, By Drug Class
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Companion Animal Pharmaceuticals Market

        • 7.4.13.1. Market Size and Forecast, By Companion Animals
        • 7.4.13.2. Market Size and Forecast, By Drug Class
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Companion Animal Pharmaceuticals Market

        • 7.4.14.1. Market Size and Forecast, By Companion Animals
        • 7.4.14.2. Market Size and Forecast, By Drug Class
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Companion Animals

      • 7.5.3. Market Size and Forecast, By Drug Class

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Companion Animal Pharmaceuticals Market

        • 7.5.6.1. Market Size and Forecast, By Companion Animals
        • 7.5.6.2. Market Size and Forecast, By Drug Class
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Companion Animal Pharmaceuticals Market

        • 7.5.7.1. Market Size and Forecast, By Companion Animals
        • 7.5.7.2. Market Size and Forecast, By Drug Class
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Companion Animal Pharmaceuticals Market

        • 7.5.8.1. Market Size and Forecast, By Companion Animals
        • 7.5.8.2. Market Size and Forecast, By Drug Class
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Companion Animal Pharmaceuticals Market

        • 7.5.9.1. Market Size and Forecast, By Companion Animals
        • 7.5.9.2. Market Size and Forecast, By Drug Class
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Companion Animal Pharmaceuticals Market

        • 7.5.10.1. Market Size and Forecast, By Companion Animals
        • 7.5.10.2. Market Size and Forecast, By Drug Class
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Companion Animal Pharmaceuticals Market

        • 7.5.11.1. Market Size and Forecast, By Companion Animals
        • 7.5.11.2. Market Size and Forecast, By Drug Class
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Eli Lily, Merck And Co., Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Ceva Santé Animale

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Vetoquinol S.A.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Zoetis

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Boehringer Ingelheim International GmbH

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. IDEXX Laboratories, Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Indian Immunologicals Ltd.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Agrolabo S.p.A.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Elanco Animal Health Incorporated

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Virbac

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DOGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR CATS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HORSES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTIBIOTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTI-INFLAMMATORY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HEART WORM DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PARASITICIDES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR NUTRITIONAL DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR BEHAVIORAL DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VACCINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR E-COMMERCE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. U.S. COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 25. U.S. COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 26. U.S. COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. CANADA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 28. CANADA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 29. CANADA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE COMPANION ANIMAL PHARMACEUTICALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. GERMANY COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 41. GERMANY COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. ITALY COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 44. ITALY COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 45. ITALY COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 48. SPAIN COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. UK COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 50. UK COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 51. UK COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. RUSSIA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 53. RUSSIA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 54. RUSSIA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. REST OF EUROPE COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 56. REST OF EUROPE COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 57. REST OF EUROPE COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 59. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 60. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 61. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. CHINA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 63. CHINA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 64. CHINA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. JAPAN COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 66. JAPAN COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 67. JAPAN COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. INDIA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 69. INDIA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 70. INDIA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 72. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 73. SOUTH KOREA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 75. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 76. AUSTRALIA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. THAILAND COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 78. THAILAND COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 79. THAILAND COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 80. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 81. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 82. MALAYSIA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. INDONESIA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 84. INDONESIA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 85. INDONESIA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. REST OF ASIA PACIFIC COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 87. REST OF ASIA PACIFIC COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 88. REST OF ASIA PACIFIC COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 89. LAMEA COMPANION ANIMAL PHARMACEUTICALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 90. LAMEA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 91. LAMEA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 92. LAMEA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 93. BRAZIL COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 94. BRAZIL COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 95. BRAZIL COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH AFRICA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 97. SOUTH AFRICA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 98. SOUTH AFRICA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. SAUDI ARABIA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 100. SAUDI ARABIA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 101. SAUDI ARABIA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 102. UAE COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 103. UAE COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 104. UAE COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 105. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 106. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 107. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 108. REST OF LAMEA COMPANION ANIMAL PHARMACEUTICALS, BY COMPANION ANIMALS, 2022-2032 ($MILLION)
  • TABLE 109. REST OF LAMEA COMPANION ANIMAL PHARMACEUTICALS, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 110. REST OF LAMEA COMPANION ANIMAL PHARMACEUTICALS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 111. ELI LILY, MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 112. ELI LILY, MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 113. ELI LILY, MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 114. ELI LILY, MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 115. ELI LILY, MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. CEVA SANTé ANIMALE: KEY EXECUTIVES
  • TABLE 117. CEVA SANTé ANIMALE: COMPANY SNAPSHOT
  • TABLE 118. CEVA SANTé ANIMALE: OPERATING SEGMENTS
  • TABLE 119. CEVA SANTé ANIMALE: PRODUCT PORTFOLIO
  • TABLE 120. CEVA SANTé ANIMALE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. VETOQUINOL S.A.: KEY EXECUTIVES
  • TABLE 122. VETOQUINOL S.A.: COMPANY SNAPSHOT
  • TABLE 123. VETOQUINOL S.A.: OPERATING SEGMENTS
  • TABLE 124. VETOQUINOL S.A.: PRODUCT PORTFOLIO
  • TABLE 125. VETOQUINOL S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. ZOETIS: KEY EXECUTIVES
  • TABLE 127. ZOETIS: COMPANY SNAPSHOT
  • TABLE 128. ZOETIS: OPERATING SEGMENTS
  • TABLE 129. ZOETIS: PRODUCT PORTFOLIO
  • TABLE 130. ZOETIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY EXECUTIVES
  • TABLE 132. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • TABLE 133. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OPERATING SEGMENTS
  • TABLE 134. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
  • TABLE 135. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. IDEXX LABORATORIES, INC.: KEY EXECUTIVES
  • TABLE 137. IDEXX LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 138. IDEXX LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 139. IDEXX LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 140. IDEXX LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. INDIAN IMMUNOLOGICALS LTD.: KEY EXECUTIVES
  • TABLE 142. INDIAN IMMUNOLOGICALS LTD.: COMPANY SNAPSHOT
  • TABLE 143. INDIAN IMMUNOLOGICALS LTD.: OPERATING SEGMENTS
  • TABLE 144. INDIAN IMMUNOLOGICALS LTD.: PRODUCT PORTFOLIO
  • TABLE 145. INDIAN IMMUNOLOGICALS LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. AGROLABO S.P.A.: KEY EXECUTIVES
  • TABLE 147. AGROLABO S.P.A.: COMPANY SNAPSHOT
  • TABLE 148. AGROLABO S.P.A.: OPERATING SEGMENTS
  • TABLE 149. AGROLABO S.P.A.: PRODUCT PORTFOLIO
  • TABLE 150. AGROLABO S.P.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. ELANCO ANIMAL HEALTH INCORPORATED: KEY EXECUTIVES
  • TABLE 152. ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT
  • TABLE 153. ELANCO ANIMAL HEALTH INCORPORATED: OPERATING SEGMENTS
  • TABLE 154. ELANCO ANIMAL HEALTH INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 155. ELANCO ANIMAL HEALTH INCORPORATED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 156. VIRBAC: KEY EXECUTIVES
  • TABLE 157. VIRBAC: COMPANY SNAPSHOT
  • TABLE 158. VIRBAC: OPERATING SEGMENTS
  • TABLE 159. VIRBAC: PRODUCT PORTFOLIO
  • TABLE 160. VIRBAC: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET
  • FIGURE 3. SEGMENTATION COMPANION ANIMAL PHARMACEUTICALS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN COMPANION ANIMAL PHARMACEUTICALS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCOMPANION ANIMAL PHARMACEUTICALS MARKET
  • FIGURE 11. COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION, BY BY COMPANION ANIMALS
  • FIGURE 12. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION, BY BY DRUG CLASS
  • FIGURE 17. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTIBIOTICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTI-INFLAMMATORY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HEART WORM DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PARASITICIDES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR NUTRITIONAL DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR BEHAVIORAL DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VACCINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 26. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR E-COMMERCE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. COMPANION ANIMAL PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 33. COMPETITIVE DASHBOARD
  • FIGURE 34. COMPETITIVE HEATMAP: COMPANION ANIMAL PHARMACEUTICALS MARKET
  • FIGURE 35. Top player positioning, 2022
  • FIGURE 36. ELI LILY, MERCK AND CO., INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. ELI LILY, MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. ELI LILY, MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. CEVA SANTé ANIMALE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. CEVA SANTé ANIMALE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. CEVA SANTé ANIMALE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. VETOQUINOL S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. VETOQUINOL S.A.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. VETOQUINOL S.A.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. ZOETIS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. ZOETIS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. ZOETIS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. IDEXX LABORATORIES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. IDEXX LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. IDEXX LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. INDIAN IMMUNOLOGICALS LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. INDIAN IMMUNOLOGICALS LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. INDIAN IMMUNOLOGICALS LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. AGROLABO S.P.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. AGROLABO S.P.A.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. AGROLABO S.P.A.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. ELANCO ANIMAL HEALTH INCORPORATED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. ELANCO ANIMAL HEALTH INCORPORATED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. ELANCO ANIMAL HEALTH INCORPORATED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. VIRBAC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. VIRBAC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. VIRBAC: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Companion Animal Pharmaceuticals Market

Start reading.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers